结直肠癌合并糖尿病患者的生存情况及血糖控制
Survival and glycemic control in patients with colorectal cancer and diabetes mellitus.
作者信息
Karlin Nina J, Amin Shailja B, Kosiorek Heidi E, Buras Matthew R, Verona Patricia M, Cook Curtiss B
机构信息
Division of Hematology and Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
Biostatistics, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
出版信息
Future Sci OA. 2018 Aug 15;4(9):FSO335. doi: 10.4155/fsoa-2018-0044. eCollection 2018 Oct.
AIM
The impact of diabetes mellitus (DM) on survival in patients with colorectal cancer and the impact of colorectal cancer on glycemic control were examined.
MATERIALS & METHODS: Patients with colorectal cancer with and without DM were matched 1:1 (2007-2015). Characteristics were compared between the two groups and survival assessed with the Kaplan-Meier method. Mixed models compared hemoglobin A and glucose levels over time.
RESULTS
In both groups, glucose values decreased during the year following cancer diagnosis (p < 0.001). 5-year overall survival was 56% (95% CI: 42-68%) for DM patients versus 57% (95% CI: 43-69%) for non-DM patients (p = 0.62).
CONCLUSION
DM did not adversely impact survival of patients with colorectal cancer. Colorectal cancer did not affect glycemic control.
目的
研究糖尿病（DM）对结直肠癌患者生存的影响以及结直肠癌对血糖控制的影响。
材料与方法
对2007年至2015年期间患有和未患有DM的结直肠癌患者进行1:1配对。比较两组患者的特征，并采用Kaplan-Meier方法评估生存率。混合模型比较了随时间变化的糖化血红蛋白和血糖水平。
结果
两组患者在癌症诊断后的一年内血糖值均下降（p < 0.001）。DM患者的5年总生存率为56%（95%置信区间：42-68%），非DM患者为57%（95%置信区间：43-69%）（p = 0.62）。
结论
DM对结直肠癌患者的生存没有不利影响。结直肠癌不影响血糖控制。
Zotero 插件